Navigation Links
XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
Date:8/26/2008

r adverse cardiac events (MACE) were reported since the one-year analysis, and the incidence of late stent thrombosis for patients treated with Custom NX was zero percent. The CUSTOM I article published in EuroIntervention was recognized by the journal's editorial board as one of the six best papers submitted to the journal during the previous winter, and Lutz Buellesfeld, M.D., of the HELIOS Heart Center in Siegburg, Germany, received an award in conjunction with the publication after presenting it at the annual EuroPCR meeting in May.

The CUSTOM II trial was designed to evaluate the safety and efficacy of Custom NX for the treatment of long and multiple lesions. Of the 100 patients enrolled, 69 patients were enrolled in the long-lesion arm, and 31 patients were enrolled in the two-lesion arm of the study. CUSTOM II enrolled one of the most difficult to treat patient populations ever studied in a DES trial. In the CUSTOM II patient population, the average vessel diameter was 2.57mm and the average lesion length was 28.7mm. Twenty-six percent of the study participants were diabetic. The percentage of patients with ACC/AHA lesion grade B2 or C was 65.1 percent. CUSTOM II's six-month clinical results have been sustained at one year. The target lesion revascularization rate remained constant at four percent, with no new MACE events, and no late stent thrombosis.

The EuroIntervention paper, titled "One year results of a new in-situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: result of the CUSTOM-II trial," can be accessed at: http://www.europcronline.com/eurointervention/15th_issue/37/.

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to c
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces European Regulatory Update
2. Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
3. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
4. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
5. XTENT Announces First Quarter 2008 Financial Results
6. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
7. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
8. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
9. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
10. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
11. Genmab Announces Upcoming Ofatumumab Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 The Physician-Patient Alliance for ... July 28, 2015, "Surviving Your Hospital Stay: Physician-Patient ... Patient Safety." A sentence was omitted ... "PPAHS is a member of the National ... more information on the National Coalition to Promote ...
(Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, asthma ... of Yujiro S. Hata to its board ... in business and corporate development is a tremendous asset ... president and chief executive officer of Xencor. "Xencor faces ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... 16 Berlin Heart Inc. today announced,its EXCOR(R) Pediatric ... ongoing IDE clinical trial in the United,States of America. ... the Investigational Plan for the IDE study of the ... approval for the prospective,IDE study to begin initially at ...
... Australia, Oct. 16 Cytopia Limited (ASX:,CYT) will ... two important,scientific meetings this month., Dr Emmanuelle ... a,lecture entitled Targeted JAK2 Inhibitors for Myeloproliferative Disorders,at ... Australia and New,Zealand, in Perth, Australia, on 21 ...
Cached Medicine Technology:Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 2Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 3Cytopia Scientific Presentations on JAK2 Inhibitor Program 2
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of ... Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto ... in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black ... Exilis non-surgical fat reduction in New York. Due to its unparalleled level of ... Many patients travel to New York to get their non-surgical skin tightening and ...
(Date:7/31/2015)... ... 2015 , ... The 2nd annual Ride to Fight On will start and ... 2015. The Ride to Fight On is a cycling fundraiser that benefits the West ... Clinic and The University of Tennessee Health Science Center. A health and wellness festival ...
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... , ... July 31, 2015 , ... M3 USA MDLinx.com, ... to launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology ... Exam Prep from MDLinx makes preparing for the exam easy and painless. MDLinx ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... cholesterol lowering drugs known as statins may help prevent future ... The study is published in the August 2, 2011, print ... American Academy of Neurology. "Because the cause of ... drugs are often not used to prevent further strokes or ...
... , MONDAY, Aug. 1 (HealthDay News) -- Teens are ... in or go to school in neighborhoods with many fast ... study finds. Researchers compared 2007 data on junk food ... of junk food outlets, such as fast food restaurants, convenience ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... who have been prescribed a controlled medication such as Oxycontin ... are misusing the drugs, a new study has found. ... abuse other substances and to start giving or selling drugs ...
... , Prostate cancer is the number two killer of American men, ... affects more than 2 million American men, and in 2010 there ... kills, but even for those who survive it, the world is ... and depression are common after-effects of prostate cancer, and until now ...
... By Serena Gordon HealthDay Reporter , MONDAY, Aug. ... of the omega 3 fatty acid DHA during pregnancy, their ... indicates. At 1 month and 3 months of age, ... in the womb experienced cold symptoms, compared to about 45 ...
... of Technology (MIT) have developed a new imaging system ... changes in the esophagus or colon. The new system, ... Biomedical Optics Express , is based on an ... a way to see below the surface with 3-D, ...
Cached Medicine News:Health News:Cholesterol-lowering drugs may help prevent recurrent strokes in younger people 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:When Teens Abuse Prescriptions, Addiction Often Follows 2Health News:When Teens Abuse Prescriptions, Addiction Often Follows 3Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 2Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 4
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, extra delicate, straight....
Medicine Products: